Alivus Life Sciences Acquires 9.21% Stake In Torrent Urja 19 To Boost Renewable Focus
NiveshIQ
NSE: ALIVUS · Healthcare
Alivus Life Sciences Ltd.
₹1,337.20▼ ₹33.00 (-2.41%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on ALIVUS. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Alivus Life Sciences Ltd.
Alivus Life Sciences Limited is a specialty API manufacturer with a global footprint spanning India, the United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China, and Australia. The company’s core revenue drivers include the production of cardiovascular, CNS, diabetes, oncology, urology, and pain‑management APIs such as amiodarone, ezetimibe, lithium carbonate, and sitagliptin, alongside a robust contract development and manufacturing services portfolio. In FY25, Alivus reported revenue of ₹2,590 Cr and net income of ₹603 Cr, reflecting a 12% YoY revenue growth and a 15% increase in operating margin. Recent strategic moves include the establishment of a wholly‑owned subsidiary in Brazil with a capital of R$500,000 to strengthen its Latin‑American presence and the ac
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹2,283 Cr +5.64% | ₹2,387 Cr +4.54% | ₹2,552 Cr +6.91% |
| EBITDA Margin | 29.53% | 28.60% | 31.24% |
| Net Profit | ₹470.89 Cr +0.84% | ₹485.63 Cr +3.13% | ₹564.48 Cr +16.24% |
| EPS | ₹38.43 | ₹39.63 | ₹45.99 |
Annual figures in Indian Rupees (Crores). Source: company filings (NSE).
Recent News
Alivus Life Sciences Ltd is Rated Hold
Alivus Life Sciences incorporates wholly owned subsidiary in Brazil
🔒
+ 3 more stories about Alivus Life Sciences Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q2FY27 results: revenue ₹682 Cr, PAT ₹197 Cr, EPS ₹16.02, EBITDA margin 38.9%. Growth context: revenue YoY +16.0%, PAT YoY +51.3%, revenue QoQ +6.5%, PAT QoQ +22.9%.
The next 2–4 quarters will be driven by product‑pipeline execution, domestic demand, export mix, regulatory approvals, a...
FY26 (last completed FY): revenue ₹2, 552 Cr, PAT ₹564 Cr, EBITDA margin 31.2%, EPS ₹45.99. Year-on-year: revenue YoY +6...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantMore Healthcare stocks
Abbott India Ltd.Acutaas Chemicals Ltd.Advanced Enzyme Tech Ltd.Ajanta Pharmaceuticals Ltd.Akums Drugs and Pharmaceuticals Ltd.Alembic Pharmaceuticals Ltd.Alkem Laboratories Ltd.Anthem Biosciences Ltd.Apollo Hospitals Enterprise Ltd.Aster DM Healthcare Ltd.AstraZenca Pharma India Ltd.Aurobindo Pharma Ltd.
Everything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for ALIVUS
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track ALIVUS alongside your other holdings
Unlock full ALIVUS research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Alivus Life Sciences Ltd.?
NiveshIQ detects active intelligence signals for Alivus Life Sciences Ltd. (ALIVUS) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Alivus Life Sciences Ltd.?
Alivus Life Sciences Ltd. operates in the Healthcare sector with a market capitalisation of ₹1,378,329.2L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.